Join to View Full Profile
83 Little Fox LnSouthbury, CT 06488
Phone+1 203-267-4058
Are you Dr. Padula?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Steven Padula, MD is a rheumatologist in Southbury, Connecticut. He is currently licensed to practice medicine in Connecticut.
Education & Training
University of ConnecticutFellowship, Rheumatology, 1982 - 1985
New York University School of MedicineClass of 1979
Certifications & Licensure
CT State Medical License 1982 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Rheumatology
Publications & Presentations
PubMed
- 7 citationsLong-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial.Philip J Mease, Herbert Kellner, Akimichi Morita, Alan J Kivitz, Stella Aslanyan
Rheumatology and Therapy. 2022-10-01 - 41 citationsEffects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind,...Sudha Visvanathan, Stefan Daniluk, Rafał Ptaszyński, Ulf Müller-Ladner, Meera Ramanujam
Annals of the Rheumatic Diseases. 2019-06-01 - 265 citationsRisankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.Dominique Baeten, Mikkel Østergaard, James Cheng-Chung Wei, Joachim Sieper, Pentti Järvinen
Annals of the Rheumatic Diseases. 2018-06-26
Press Mentions
IL-23 Inhibitor Risankizumab Induces Remission in Phase II Study in Patients with Moderate-to-Severe Crohn’s DiseaseMay 24th, 2016
